Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

← catalyst calendar

NCT06263231 · readout ≤ 499 d

Sponsored by Intensity Therapeutics, Inc. (industry) · INTS — their whole pipeline →. With Premier Research.

Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
333estimated
Sites
17
Countries
Canada, France, Germany +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-06-28actualWhen the study began enrolling
Primary completionDec 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2028estimatedThe whole study's end, after follow-up
First posted2024-02-16actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-11actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Sarcoma,Soft Tissue

Interventions

  • Drug: INT230-6
  • Drug: Eribulin
  • Drug: Trabectedin
  • Drug: Pazopanib

Primary outcome

what the primary-completion date above is the date OF
Overall Survival (OS)
measured From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INTS's whole pipeline · Catalyst calendar · Every registered study · What changed